MENU
+Compare
ARVN
Stock ticker: NASDAQ
AS OF
Nov 13 closing price
Price
$10.12
Change
-$0.29 (-2.79%)
Capitalization
650.27M

ARVN Arvinas Forecast, Technical & Fundamental Analysis

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins... Show more

Industry: #Biotechnology
ARVN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ARVN with price predictions
Nov 12, 2025

ARVN in +5.46% Uptrend, growing for three consecutive days on November 11, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARVN advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 05, 2025. You may want to consider a long position or call options on ARVN as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARVN just turned positive on November 07, 2025. Looking at past instances where ARVN's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 170 cases where ARVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ARVN moved out of overbought territory on November 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARVN broke above its upper Bollinger Band on November 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.152) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (2.355) is also within normal values, averaging (322.723).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ARVN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARVN is expected to report earnings to rise 3.23% to -49 cents per share on March 02

Arvinas ARVN Stock Earnings Reports
Q4'25
Est.
$-0.50
Q3'25
Beat
by $0.23
Q2'25
Beat
by $0.10
Q1'25
Beat
by $2.14
Q4'24
Beat
by $0.33
The last earnings report on November 05 showed earnings per share of -47 cents, beating the estimate of -70 cents. With 1.33M shares outstanding, the current market capitalization sits at 650.27M.
A.I. Advisor
published General Information

General Information

a developer of therapies to degrade disease-causing proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHSKX72.620.70
+0.97%
BlackRock Health Sciences Opps K
READX15.930.05
+0.31%
Lazard Emerging Markets Eq Advtg R6
HSEIX12.300.03
+0.24%
Hartford Small Cap Value I
LZSMX10.530.01
+0.10%
Lazard Global Small Cap Eq Open
FBTIX40.60N/A
N/A
Fidelity Advisor Biotechnology I

ARVN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-7.14%
AXON - ARVN
46%
Loosely correlated
-0.47%
VCYT - ARVN
46%
Loosely correlated
-0.84%
ERAS - ARVN
40%
Loosely correlated
+12.29%
ATXS - ARVN
40%
Loosely correlated
+0.32%
SRPT - ARVN
40%
Loosely correlated
+0.11%
More